You are about to review presentations, reports, filings and/or other materials regarding Amarin Corporation plc (NASDAQ: AMRN) that contain time-sensitive information. The information contained therein is only current as of the date thereof and may not be a complete listing of all documents filed with the Securities Exchange Commission, made public or provided to Amarin shareholders.

Amarin expressly disclaims any obligation to review, update or correct these materials after the date thereof. Amarin may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.

Certain statements made on this web site or in materials accessed in or through the investor relations section of our web site are "forward-looking statements," which are subject to risks and uncertainties, and Amarin's actual results may differ (possibly materially) from those indicated in such statements. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q.

This website is not an offer or a solicitation to buy or sell securities. Please be aware that decisions regarding investments are the responsibility of users. Although this website includes information regarding pharmaceuticals (including products under development), the information is not intended as any advertisement and/or medical advice.

This information is intended for communication with investors and should not be construed as marketing the use of any Amarin products or product candidates.

Information on this website may be revised without any prior notice.

Company Profile

Company Profile

Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa (icosapent ethyl) is Amarin's first FDA-approved drug and is available by prescription. For more information about Vascepa visit www.vascepa.com.

The Company’s first drug, Vascepa (icosapent ethyl) is FDA-approved in the United States for treatment of patients with very high triglyceride levels (TG ≥500 mg/dL). The drug is also available by prescription in Lebanon and the United Arab Emirates. Amarin’s commercial partners are pursuing additional regulatory approvals for Vascepa in Canada, China and the Middle East and Amarin is evaluation potential commercial partnership arrangements for other countries while prioritizing promotion of Vascepa in the United States through Amarin’s sales team. In addition, the company has successfully completed a globally conducted, cardiovascular outcomes study with results which show that Vascepa lowers cardiovascular risk in patients with cardiovascular risk factors which cannot be addressed with cholesterol managing drugs alone. Amarin plans to seek expanded labeling for Vascepa to reflect the results of this outcomes study, called the REDUCE-IT study.

Vascepa (icosapent ethyl) capsules are a single-molecule prescription product consisting of the omega-3 acid commonly known as EPA in ethyl-ester form. Vascepa is not fish oil, but is derived from fish through a stringent and complex FDA-regulated manufacturing process designed to effectively eliminate impurities and isolate and protect the single molecule active ingredient from degradation. Vascepa, known in scientific literature as AMR101, has been designated a new chemical entity by the FDA. Amarin has been issued multiple patents internationally based on the unique clinical profile of Vascepa, including the drug’s ability to lower triglyceride levels in relevant patient populations without raising LDL-cholesterol levels. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

If you are reporting an adverse event or product complaint, please email amarinmi@druginfo.com or call the Amarin Call Center at 1 855 VASCEPA.

Amarin reported primary results of the successful REDUCE-IT trial concurrent with presentation of these results at the 2018 Scientific Sessions of the American Heart Association on November 10, 2018 in Chicago, Illinois. Results can be found in our press release. Additional references to such results are provided in a slide presentation of such results and in our results investor presentation.

Amarin is headquartered in Dublin, Ireland. In the U.S., the company's office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

Home Menus

Corporate Governance

The Board of Directors of Amarin Corporation plc (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.